Monthly Communication Report

Corporation:	Gilead Sciences Canada
Associated registration:	959600-360912-19
Communication date:	2026-04-15
Posted date:	2026-05-15

Designated Public Office Holders who participated in the communication:	Mackenzy Metcalfe, Policy Advisor Office of the Minister of Finance, Finance Canada (FIN) Ritu Banerjee, Assistant Deputy Minister Health Emergency Readiness Canada, Innovation, Science and Economic Development Canada (ISED) Sandenga Yeba, Director of Policy & Deputy Chief of Staff Office of the Minister of Health, Health Canada (HC) Shalene Curtis-Micallef, Deputy Minister Deputy Minister's Office, Health Canada (HC) Justine Frame, Policy Advisor Minister's Office, Health Canada (HC) Elizabeth Wong, Senior Policy Advisor Treasury Board Of Canada Secretariat (TBS) Jocelyne Voisin, Senior Assistant Deputy Minister Health Policy Branch, Health Canada (HC) Annahat Kochhar, Policy Advisor Treasury Board Of Canada Secretariat (TBS) Pamela Aung-Thin, Assistant Deputy Minister Health Products and Food Branch, Health Canada (HC) Nasser Haidar, Senior Policy Advisor Office of the Min. responsible for Canada-U.S. Trade, Intergovernmental Affairs and One Canadian Economy, Intergovernmental Affairs Secretariat (IGA) Maggie Chi, Member of Parliament House of Commons
List of Details Subject matter Detail Health, Science and Technology Canada's Drug Agency (CDA) policies as it relates to health economics assessment and recommendations made on new medicines. Health, Intellectual Property, Science and Technology Food and Drug regulations as it relates to data protection and the regulation and protection of biopharmaceutical products Economic Development, Health, Industry, Intellectual Property, International Relations, International Trade, Research and Development, Science and Technology Free Trade agreements as they relate to the biopharmaceutical industry Economic Development, Employment and Training, Health, Industry, Intellectual Property, Research and Development, Science and Technology Innovation Agenda, particularly with respect to initiatives to support and attract investments in the life sciences sector Health, National Security/Security, Science and Technology Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations Economic Development, Health, Industry, Intellectual Property, International Relations, International Trade, Research and Development, Science and Technology Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations.
Responsible Officer who filed this communication report:	Paul Petrelli
As the most senior paid officer, the person named above is responsible for certifying the communication report for the corporation or organization (Registrant). This person may or may not have participated in the reported communication. The Lobbyists Registration Regulations do not require that the names of in-house lobbyists (i.e. employees of corporations or organizations) who actually participated in the communication be disclosed.